Raymond March, Ph.D.
Assistant Professor of Economics
Bio
Raymond March is a scholar at the Challey Institute for Global Innovation and Growth with the Center for the Study of Public Choice and Private Enterprise and an assistant professor of economics in the Department of Agribusiness and Applied Economics at North Dakota State University. He teaches courses in microeconomics, the history of economic thought, and health economics. His research examines the public and private provision and governance of health care in the United States, particularly in pharmaceutical markets. His research has appeared in Southern Economic Journal, Public Choice, Research Policy, Journal of Institutional Economics, and other academic publications. He co-edited the 2022 book Pandemics and Liberty. Dr. March is a research fellow at the Independent Institute and director of FDAReview.org, an educational research and communications project on the U.S. Food and Drug Administration (FDA). He regularly blogs on health policy at The Beacon and the American Institute for Economic Research.
Education
- Ph.D., Agricultural and Applied Economics, Texas Tech University
- M.A., Agricultural and Applied Economics, Texas Tech University
- B.S., Economics and Business Management, Florida Gulf Coast University
Expertise
- Health care economics
- Regulations
- Food and Drug Administration (FDA)
- Pharmaceutical markets
- Drug pricing
- Rural health and telemedicine
Recent Research
Recent Media
Blog | Independent Institute | Did Healthcare Spending Really Return to Pre-Pandemic Levels? |
Blog | Independent Institute | Another Infant Formula Shortage? Blame the FDA |
Article | NPR | These Are Some Christmas Traditions Around the World, From Fistfights to KFC |
Op-Ed | The Hill | Political Promises Won't End Drug Shortages |
Blog | Independent Institute | Gene Therapy: A Promising Medical Frontier Hindered by Regulatory Roadblocks |
Blog | Independent Institute | Who Should Decide if Weight-Loss Injections Should be Prescribed for Kids? |
Blog | Independent Institute | More Oversight Won't Help the US Baby Formula Market |
Blog | Independent Institute | The FDA Should Stay Away from Laboratory Developed Tests |
AIER | Psychedelics Will Help America's Mental Health Crisis - If the FDA Lets Them |
DC Journal | Decongestant Drug Doesn't Work? Neither Does the FDA |
MoneyGeek | Expert Advise on Best Health Insurance Option When Unemployed |
Blog | Independent Institute | The Pandemic is Over, But Pandemic Policies Are Not |
Blog | Catalyst | The Mental Health Crisis and FDA Hurdles |
Blog | Independent Institute | FDA Efforts to Curb Youth Vaping Continue to Come Up Short |
Blog | Independent Institute | The FDA Loosens Blood Donation Restrictions, Finally |
Blog | Independent Institute | Recent Attacks on Recreational Marijuana Legalization Are All Smoke |
WalletHub | Average Car Insurance Cost |
MoneyGeek | Expert Advice on Most Affordable Health Insurance In North Dakota |
MoneyGeek | Expert Advice: Health Insurance Costs |
MoneyGeek | Expert Advice: Finding the Best Health Insurance |
Blog | Independent Institute | FDA's Rare Positive Move |
Blog | Independent Institute | Insulin Price-Caps: A Solution or a Recipe for Rationing? |
Blog | Independent Institute | Are Insulin Prices About to Drop? The Devil is in the Details |
Blog | Independent Institute | When is a Drug Safe and Effective Enough? |
Blog | Independent Institute | The FDA is Too Little Too Late in Tinkering with COVID-19 Booster Schedules |
Blog | Independent Institute | Deregulation Remains Our Best Hope to Combat Alzheimer's Disease |
Edited Volume | Pandemics and Liberty |
Blog Contributor | Independent Institute |
Blog Contributor | American Institute for Economic Research |
AIER | Pandemics and Liberty: An Introduction |
WebMD | Could Pot Prevent a Pot Belly? Researchers Get the Skinny on Cannabis |
Stranded Technologies Podcast | The Case Against the FDA |
Fortune | The FDA Could Easily Solve the Baby Formula Shortage by Allowing More Imports from Europe |
The Forum of Fargo-Moorhead | Competition, Not More Regulation, is Needed to Lower Insulin Costs |